Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: West pharmaceutical services - You Need To See This

What Are Wall Street Analysts' Target Price for West Pharmaceutical Services Stock?

West Pharmaceutical Services has substantially underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects, with price targets suggesting significant upside potential.

5 Set It and Forget It Dividend Aristocrats for a Lifetime of Income

5 Set It and Forget It Dividend Aristocrats for a Lifetime of Income

Five Dividend Aristocrats with decades of payout growth offer reliable income, resilient business models, and analyst-backed upside across sectors.

Dividend Aristocrats Offer Safety in Market Storms. Buy These 2 Top-Rated Stocks Now.

Dividend Aristocrats Offer Safety in Market Storms. Buy These 2 Top-Rated Stocks Now.

Dividend Aristocrats bring the calm with steady paychecks, making these two 'Strong Buy'-rated stocks worth a second look here.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty

These companies offer consistent dividend growth and a strong industry presence.

Is West Pharmaceutical Services Stock Underperforming the S&P 500?

West Pharmaceutical Services has lagged behind the broader S&P 500 Index over the past year, but analysts remain highly optimistic about its future growth potential.

3 Top-Rated Dividend Aristocrats to Buy Now for Passive Income

These three companies have increased their dividends for 25-plus years and offer a mix of stability, growth potential, and attractive yields.

Are Wall Street Analysts Predicting West Pharmaceutical Services Stock Will Climb or Sink?

West Pharmaceutical Services has underperformed the broader market over the past year, but Wall Street analysts remain optimistic about the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Near-oversold Dividend Aristocrats To Buy Before They Pop

3 Near-oversold Dividend Aristocrats To Buy Before They Pop

These three Dividend Aristocrats trade near oversold levels and offer reliable income and potential capital appreciation.

5 Stocks With Rock-Solid Balance Sheets

5 Stocks With Rock-Solid Balance Sheets

As markets get wobbly amid a lack of interest rate clarity, Goldman Sachs has called out these 5 stocks for their industry-leading balance sheet strength.

1

Organisations

Abbott Laboratories

Arista Networks

Intuitive Surgical

Barchart Opinion

Monolithic Power

West Pharmaceutical

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

368,607 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play